The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ICML 2019 | Agressive or transformed MCL: prognostic factors, outcomes & mutational profile

Name: Agressive or transformed MCL: prognostic factors, outcomes & mutational profile
Uploaded: 2019-07-02T09:44:44.000Z
Duration: 2 min 18 s
Description: Preetesh Jain, MD, PhD, MD Anderson Cancer Center, Houston, Texas, TX, presents the comprehensive analysis of prognostic factors, outcomes and mutation profiles in patients with mantle cell lymphoma (MCL) with an aggressive histology (blastoid/pleomorphic) or transformed MCL. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Preetesh Jain • 2 Jul 2019

ICML 2019

B-Cell Lymphoma Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma

Preetesh Jain, MD, PhD, MD Anderson Cancer Center, Houston, Texas, TX, presents the comprehensive analysis of prognostic factors, outcomes and mutation profiles in patients with mantle cell lymphoma (MCL) with an aggressive histology (blastoid/pleomorphic) or transformed MCL. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.